Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
SG&A Expense Growth TrendStable
Percentile Rank74
3Y CAGR+23.2%
5Y CAGR-33.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+23.2%/yr
Quarterly compound
5Y CAGR
-33.9%/yr
Recent acceleration
Percentile
P74
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 16.02% |
| Q3 2025 | 11.98% |
| Q2 2025 | -6.99% |
| Q1 2025 | -0.84% |
| Q4 2024 | 8.00% |
| Q3 2024 | -12.44% |
| Q2 2024 | 3.31% |
| Q1 2024 | 16.27% |
| Q4 2023 | -10.77% |
| Q3 2023 | 6.34% |
| Q2 2023 | 8.54% |
| Q1 2023 | -1.54% |
| Q4 2022 | 8.56% |
| Q3 2022 | 11.52% |
| Q2 2022 | -1.44% |
| Q1 2022 | 21.50% |
| Q4 2021 | 10.60% |
| Q3 2021 | 36.35% |
| Q2 2021 | 56.25% |
| Q1 2021 | 7.62% |
| Q4 2020 | 126.81% |
| Q3 2020 | 68.95% |
| Q2 2020 | 13.18% |
| Q1 2020 | 0.00% |